Abeta25-35 induces rapid lysis of red blood cells: contrast with Abeta1-42 and examination of underlying mechanisms

Brain Res. 1997 Oct 10;771(1):147-53. doi: 10.1016/s0006-8993(97)00824-x.

Abstract

Amyloid beta-peptide (A beta) is produced by many different cell types and circulates in blood and cerebrospinal fluid in a soluble form. In Alzheimer's disease (AD), A beta forms insoluble fibrillar aggregates that accumulate in association with cells of the brain parenchyma and vasculature. Both full-length A beta (A beta1-40/42) and the A beta25-35 fragment can damage and kill neurons by a mechanism that may involve oxidative stress and disruption of calcium homeostasis. Circulating blood cells are exposed to soluble A beta1-40/42 and may also be exposed to A beta aggregates associated with the luminal surfaces of cerebral microvessels. We therefore examined the effects of A beta25-35 and A beta1-42 on human red blood cells (RBCs) and report that A beta25-35, in contrast to A beta1-42, induces rapid (10-60 min) lysis of RBCs. The mechanism of RBC lysis by A beta25-35 involved ion channel formation and calcium influx, but did not involve oxidative stress because antioxidants did not prevent cell lysis. In contrast, A beta1-42 induced a delayed (4-24 h) damage to RBCs which was attenuated by antioxidants. The damaging effects of both A beta25-35 and A beta1-42 towards RBCs were completely prevented by Congo red indicating a requirement for peptide fibril formation. A beta1-42 induced membrane lipid peroxidation in RBC, and basal levels of lipid peroxidation in RBCs from AD patients were significantly greater than in age-matched controls, suggesting a possible role for A beta1-42 in previously reported alterations in RBCs from AD patients.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Amyloid beta-Peptides / pharmacology*
  • Congo Red / pharmacology
  • Erythrocytes / drug effects
  • Erythrocytes / physiology*
  • Hemolysis / drug effects*
  • Humans
  • In Vitro Techniques
  • Ion Channels / physiology
  • Kinetics
  • Lipid Peroxidation / drug effects
  • Membrane Lipids / blood
  • Neurons / drug effects
  • Neurons / pathology
  • Peptide Fragments / pharmacology*
  • Structure-Activity Relationship

Substances

  • Amyloid beta-Peptides
  • Ion Channels
  • Membrane Lipids
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • amyloid beta-protein (25-35)
  • Congo Red